What are the side effects of margetuximab? Who cannot use it?

Margetuximab, a monoclonal antibody targeting HER2-positive tumors, has achieved good clinical results in the treatment of breast cancer and gastric cancer. However, like other biologics, margetuximab may cause some side effects. Common side effects include immune-related reactions, allergic reactions, gastrointestinal discomfort, and hematological abnormalities. Immune reactions usually manifest as symptoms such as fever, chills, rash, dyspnea or hypotension, especially during the first dose. These symptoms are common and need to be dealt with under clinical observation.

In addition, margituximab may cause gastrointestinal reactions such as nausea, vomiting, and diarrhea, especially when used in combination with chemotherapy. These side effects may be more obvious. Regarding the cardiovascular system, margituximab may sometimes cause symptoms such as hypotension, heart failure, tachycardia, etc. Therefore, patients with cardiovascular problems need to be careful and monitored when using this drug. During treatment, heart function needs to be checked regularly to detect potential problems in time.

The use of margetuximab may also cause hematological side effects, such as leukopenia, anemia, and thrombocytopenia. Especially during chemotherapy, these side effects will be more obvious, so regular blood routine monitoring is required. These hematological abnormalities may increase the patient's risk of infection. Patients should pay attention to avoiding infection during treatment and promptly report any discomfort to the doctor.
Although margetuximab has a good therapeutic effect, not all people are suitable for use.孕妇和哺乳期妇女应避免使用该药物，因为它可能对胎儿产生不良影响，且可能通过乳汁分泌。 In addition, patients with a history of serious heart disease or immune system disorders should carefully assess the risks before use. In these special groups, the use of margetuximab may increase the occurrence of adverse reactions and needs to be used under the guidance of a professional physician.
Reference: https://www.margenza.com/